ImmuneRegen to present radiation treatment to US government

Radilex is currently in development for treating toxic radiation exposure, including Acute Radiation Sickness. Recent testing of the drug using Total Body Irradiation (TBI) in an animal model showed a 50% survival rate among mice treated with Radilex following lethal irradiation.

Additional tests have provided evidence that Radilex is a prospective countermeasure for many chemical threats, and could possibly demonstrate efficacy against many chemical and biological agents as well.

The data to be presented will provide the initial steps in designing a program with the goal of discovering and developing specific post-exposure therapeutics and diagnostic tools for eventual inclusion in the Strategic National Stockpile. ImmuneRegen BioSciences has begun preparations to produce Radilex on a large scale should such potential purchases occur.

The primary objective of the National Institutes of Health program will be to develop medical countermeasures against chemical threat agents. The civilian chemical threat spectrum involves chemical warfare agents, toxic industrial chemicals (TICs), plant/animal toxins, and other chemical threats. These include neurotoxic compounds, such as organophosphorus nerve agents; vesicating agents, such as sulfur mustard; pulmonary toxicants, such as chlorine gas; and metabolic/cellular poisons, such as cyanide.

“We believe that Radilex is at the forefront of becoming a Universal Bioterror Protectant,” commented Michael Wilhelm, CEO of ImmuneRegen Biosciences. “After completing six rounds of animal testing with lethal dosages of radiation, Radilex has shown a 50% survival rate. We have confidence that further testing of Radilex and its complementary agent Homspera will show similar results for anthrax, ricin, mustard gas, and other threats to the respiratory and immune systems.”